Sugi Predict

Sugi Predict / Compounds / SCHEMBL1373967

SCHEMBL1373967

SCHEMBL1373967

CC1(C)OB(c2ccc(OCCCCl)cc2)OC1(C)C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.50
▸ CA2 P00918 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ LPL P06858 12/20 0.47
▸ LIPG Q9Y5X9 12/20 0.47
▸ DGAT1 O75907 1/20 0.44
▸ F11 P03951 1/20 0.42
▸ AAK1 Q2M2I8 1/20 0.42
▸ HIF1A Q16665 2/20 0.41
▸ CA12 O43570 1/20 0.40
▸ CA3 P07451 1/20 0.40
▸ CA4 P22748 1/20 0.40
▸ CA6 P23280 1/20 0.40
▸ CA5A P35218 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ CA5B Q9Y2D0 1/20 0.40
▸ ESR2 Q92731 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2972782 0.95 CA1 (0.49) CA1CA2CA9LPLLIPG
SCHEMBL29455775 0.93 CA1 (0.50) CA1CA2CA9LPLLIPG
SCHEMBL430495 0.90 LPL (0.53) CA1CA2CA9LPLLIPG
SCHEMBL428838 0.90 LPL (0.53) CA1CA2CA9LPLLIPG
SCHEMBL428836 0.90 LPL (0.53) CA1CA2CA9LPLLIPG
SCHEMBL25405585 0.90 LPL (0.53) CA1CA2CA9LPLLIPG
SCHEMBL427591 0.90 CA1 (0.56) CA1CA2CA9LPLLIPG
SCHEMBL14302548 0.88 LPL (0.61) CA1CA2CA9LPLLIPG
SCHEMBL30771573 0.86 LPL (0.45) CA1CA2CA9LPLLIPG
SCHEMBL18727880 0.85 LPL (0.62) CA1CA2CA9LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025106926-A1 CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF Praxis Biotech LLC (US) 2025-05-22 — — WO disclosed
WO-2025106939-A1 CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF Praxis Biotech LLC (US) 2025-05-22 — — WO disclosed
EP-2502918-B1 Pyridazinone Derivatives CEPHALON INC (US) 2015-03-25 — — EP disclosed
US-20140142088-A1 PYRIDAZINONE DERIVATIVES CEPHALON, INC. (US) 2014-05-22 — — US disclosed
US-8673916-B2 Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives CEPHALON, INC. (US) 2014-03-18 — — US disclosed
US-8586588-B2 Aryl pyridazinone derivatives and their use as H3 receptor ligands CEPHALON, INC. (US) 2013-11-19 — — US disclosed
EP-2069312-B1 PYRIDIZINONE DERIVATIVES CEPHALON INC (US) 2012-11-07 — — EP disclosed
EP-2502918-A1 Pyridizinone Derivatives Cephalon, Inc. (US) 2012-09-26 — — EP disclosed
EP-2492263-A1 Pyridizinone Derivatives Cephalon, Inc. (US) 2012-08-29 — — EP disclosed
US-8247414-B2 Pyridizinone derivatives and the use thereof as H3 inhibitors CEPHALON, INC. (US) 2012-08-21 — — US disclosed
US-8207168-B2 Pyridazinone derivatives CEPHALON, INC. (US) 2012-06-26 — — US disclosed
US-8158652-B2 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases MSD K.K. (JP) 2012-04-17 — — US disclosed
US-20110288075-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2011-11-24 — — US disclosed
US-20100280007-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2010-11-04 — — US disclosed
US-20100273779-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2010-10-28 — — US disclosed
EP-2069312-A2 PYRIDIZINONE DERIVATIVES Cephalon, Inc. (US) 2009-06-17 — — EP disclosed
US-20080269287-A1 Substituted Pyridone Derivative MSD K.K. (JP) 2008-10-30 — — US disclosed
WO-2008013838-A2 PYRIDIZINONE DERIVATIVES CEPHALON, INC. (US) 2008-01-31 — — WO disclosed
US-20080027041-A1 Pyridizinone derivatives CEPHALON, INC. (US) 2008-01-31 — — US disclosed
EP-1820797-A1 SUBSTITUTED PYRIDONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269287-A1 Substituted Pyridone Derivative HRH3, HRH4, HRH1 CA1 4369/4885CA2 3661/4885CA9 4504/4885
US-20080027041-A1 Pyridizinone derivatives H1-5, H1-3, H1-4 CA1 4298/4885CA2 2801/4885CA9 3177/4885
US-20100280007-A1 Pyridazinone Derivatives HRH3, HNMT, HRH4 CA1 4082/4885CA2 3680/4885CA9 4773/4885
US-20110288075-A1 Pyridazinone Derivatives HRH3, HNMT, HRH4 CA1 4005/4885CA2 3585/4885CA9 4745/4885
US-20140142088-A1 PYRIDAZINONE DERIVATIVES HRH3, HNMT, HRH4 CA1 4135/4885CA2 3687/4885CA9 4776/4885
US-20100273779-A1 Pyridazinone Derivatives HRH3, HNMT, HRH4 CA1 4082/4885CA2 3680/4885CA9 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.